Blueprint Medicines is a biotechnology business based in the US. Blueprint Medicines shares (BPMC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $101.84 – an increase of 15.09% over the previous week. Blueprint Medicines employs 649 staff and has a trailing 12-month revenue of around $508.8 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $101.84 |
|---|---|
| 52-week range | $73.04 - $121.90 |
| 50-day moving average | $87.98 |
| 200-day moving average | $94.11 |
| Wall St. target price | $124.75 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.07 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $104.64 from 2025-05-02
| 1 week (2025-04-28) | 18.22% |
|---|---|
| 1 month (2025-04-04) | 28.11% |
| 3 months (2025-02-06) | -4.54% |
| 6 months (2024-11-06) | 5.03% |
| 1 year (2024-05-06) | -1.52% |
|---|---|
| 2 years (2023-05-05) | 86.09% |
| 3 years (2022-05-05) | 73.45% |
| 5 years (2020-05-05) | 75.16% |
| Revenue TTM | $508.8 million |
|---|---|
| Gross profit TTM | $488.7 million |
| Return on assets TTM | -11.89% |
| Return on equity TTM | -31.26% |
| Profit margin | -13.19% |
| Book value | $4.69 |
| Market Capitalization | $5.8 billion |
TTM: trailing 12 months
We're not expecting Blueprint Medicines to pay a dividend over the next 12 months.
Over the last 12 months, Blueprint Medicines's shares have ranged in value from as little as $73.04 up to $121.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines's is 0.746. This would suggest that Blueprint Medicines's shares are less volatile than average (for this exchange).
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc. ; Hoffmann-La Roche Inc.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.